Filing Flows › Guardian Pharmacy Services (GRDN) › Stock forecast & fair value
Guardian Pharmacy Services (GRDN) stock forecast and fair value
Guardian Pharmacy Services (GRDN) trades at $42.39. 7 analysts' median price target is $50.00 (+18%), from $47.00 to $52.00. Across 27 valuation methods the middle fair value is $20.83 (-51%); the DCF says $21.21.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | −$25.37 | $24.35 | $87.09 | -43% |
| DCF — Monte Carlo 10th–90th percentile | −$23.18 | $21.21 | $60.28 | -50% |
| P/E vs peers | $12.94 | $22.02 | $29.95 | -48% |
| P/E vs peers, weighted | $17.77 | $24.87 | $38.23 | -41% |
| P/E vs peers, matched | $12.02 | $17.80 | $28.56 | -58% |
| EV/EBITDA vs peers | $14.97 | $20.27 | $33.30 | -52% |
| EV/EBITDA vs peers, weighted | $15.90 | $24.84 | $30.69 | -41% |
| EV/EBITDA vs peers, matched | $13.26 | $18.90 | $24.86 | -55% |
| EV/Sales vs peers | $16.14 | $20.83 | $34.25 | -51% |
| EV/Sales vs peers, weighted | $13.65 | $25.38 | $47.53 | -40% |
Guardian Pharmacy Services' latest quarter
Guardian Pharmacy Services, Q3 2026: revenue $371M (-2% year over year), operating margin 6.8%, net earnings $18.7M, operating cash flow $43.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for GRDN stock?
The median of 7 analysts' 12-month targets is $50.00, +18% from $42.39; the range is $47.00 to $52.00. The average rating is strong buy.
What is Guardian Pharmacy Services' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $0.88 and $49.86, with a middle value of $20.83 against a price of $42.39. Each method's assumptions are on the page.
Does Guardian Pharmacy Services usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is GRDN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.